AstraZeneca has assembled an academia-industry consortium to unravel the role of apolipoprotein E in Alzheimer's disease. The team hopes to uncover basic mechanisms about how APOE drives the disease process and to discover therapeutics tailored for carriers of the AD-associated APOE4 allele.